CCL2 and glomerulosclerosis: This immunomodulation effectively suppresses the renal expression of IL-17A and monocyte chemoattractant protein-1 (MCP-1), decelerating glomerulosclerosis progression in experimental DN models, as reported by Kidney International (109, 110).